OTCMKTS:OMBP

Omni Bio Pharmaceutical (OMBP) Stock Price, News & Analysis

$0.0010
0.00 (0.00%)
(As of 08/18/2020)
Today's Range
$0.0010
$0.0010
50-Day Range
N/A
52-Week Range
$0.00
$0.04
Volume
N/A
Average Volume
N/A
Market Capitalization
N/A
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A

About Omni Bio Pharmaceutical

Omni Bio Pharmaceutical, Inc. operates as a biopharmaceutical company in the United States. It holds a license to use patent for the treatment of diabetes using plasma-derived alpha-1 antitrypsin (p-AAT), a protein that is purified from human blood. The company also holds licenses for the use of patents and patent applications covering the use of p-AAT in the treatment of cellular transplantation and graft rejection, radiation protection, bacterial and viral diseases, myocardial remodeling, and inflammatory bowel disease indications. In addition, it holds licenses for patent applications covering compositions of various Fc-AAT constructs. Omni Bio Pharmaceutical, Inc. was founded in 2006 and is headquartered in Fort Collins, Colorado.

OMBP Stock Price History

OMBP Stock News Headlines

Zhejiang Wolwo Bio-Pharmaceutical Co Ltd Class A
Did You Get Your Free Bitcoin Yet?
And my special guest is willing to give you $10 in Bitcoin (BTC) if you take it seriously. Right now is a very important time to pay attention to what we are doing and what is happening. If you wait... it will be too late. This week we are holding several workshops and if you attend and pay attention my special guest is going to send you $10 in Bitcoin.
Shanxi Jinbo Bio pharmaceutical Co Ltd 832982
Sinopep Allsino Bio Pharmaceutical Co Ltd Class A
Did You Get Your Free Bitcoin Yet?
And my special guest is willing to give you $10 in Bitcoin (BTC) if you take it seriously. Right now is a very important time to pay attention to what we are doing and what is happening. If you wait... it will be too late. This week we are holding several workshops and if you attend and pay attention my special guest is going to send you $10 in Bitcoin.
BioMarin Pharmaceutical
Zhejiang Wolwo Bio-Pharmaceutical Co Ltd
Sinopep Allsino Bio Pharmaceutical Co Ltd (688076)
See More Headlines
Receive OMBP Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Omni Bio Pharmaceutical and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Today
4/25/2024
Fiscal Year End
3/31/2025

Industry, Sector and Symbol

Sector
Medical
Industry
Biological products, except diagnostic
Sub-Industry
N/A
Current Symbol
OTCMKTS:OMBP
Fax
N/A
Employees
1
Year Founded
N/A

Profitability

Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A

Miscellaneous

Free Float
N/A
Optionable
Not Optionable
Beta
N/A
7 AI Stocks to Invest In: An Introduction to AI Investing For Self-Directed Investors Cover

As the AI market heats up, investors who have a vision for artificial intelligence have the potential to see real returns. Learn about the industry as a whole as well as seven companies that are getting work done with the power of AI.

Get This Free Report

OMBP Stock Analysis - Frequently Asked Questions

How have OMBP shares performed in 2024?

Omni Bio Pharmaceutical's stock was trading at $0.0010 at the start of the year. Since then, OMBP shares have increased by 0.0% and is now trading at $0.0010.
View the best growth stocks for 2024 here
.

What other stocks do shareholders of Omni Bio Pharmaceutical own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Omni Bio Pharmaceutical investors own include Xenon Pharmaceuticals (XENE), aTyr Pharma (LIFE), 23895 (GKX.V) (GKX), Flexion Therapeutics (FLXN), Biocept (BIOC) and Acorda Therapeutics (ACOR).

How do I buy shares of Omni Bio Pharmaceutical?

Shares of OMBP stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (OTCMKTS:OMBP) was last updated on 4/25/2024 by MarketBeat.com Staff

From Our Partners